← Russell 3000 cross-section

ARVN ARVINAS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$603m
Revenue TTM
$317m
Net income TTM
$9m
Free cash flow
$-209m
Composite score
44.2
Sector rank
#2305

Valuation

P / E
64.9
EV / EBITDA
EV / sales
0.1
FCF yield
-34.61%
Earnings yield vs 10-yr
-3.19pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.9%
EBITDA margin
ROE
1.6%
ROIC
Revenue growth
-15.1%

Insider activity, last 90 days

Net open-market
$-0.07m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We and Pfizer are also eligible to receive up to an additional $320.0 million as contingent payments based on future development, regulatory and commercial milestones being met, as well as tiered royalties in the mid-teens to mid-20s based upon worldwide net sales of VEPPANU, subject to reduction under certain circumstances as provided in the Rigel License Agreement. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of assets and equity interests, proceeds from our collaborations and licensing arrangements, an asset sale, grant funding and debt financing. …ARVINAS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →